Managing PsA disease activity across GRAPPA domains with a JAKi: how could a domain-based framework inform care for your patients with PsA? Explore efficacy & safety data. Hear expert insights. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/SNFoejGl7g https://t.co/tmymFIi3zz

What is the most widely shared physician concern regarding the use of augmented intelligence? Take this week's RheumIQ quiz to find out. https://t.co/SkXNtYJk2v https://t.co/fOKS5clUz5

Do patients with chronic pain have double the rates of smoking compared to those without pain? Take this week's RheumIQ quiz to find out. https://t.co/rmB55KC7Zh https://t.co/ms3G9uBMd5

IN 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z https://t.co/zVHdVA2puZ

Mevalonate kinase deficiency (AKA hyper-IgD syndr-HIDS) is a rare autosomal recessive autoinflammatory dz of the MVK gene w/ exaggerated innate immunity & incr IL-1β production. Usually Dx in kids, milder forms of periodic fever syndrome have been seen in adults. https://t.co/0hAIz4JgY3

Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than placebo & equal to MTX regarding annual xray progression scores. Evidence in favor BUT failed to study monoRx vs Combo Rx https://t.co/eHdRPAcnkd https://t.co/1odwJjyL6A

ACR Backs the Provider Reimbursement Stability Act The ACR thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and https://t.co/15xU3DGD34

In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and implications. 🎧 Listen here: https://t.co/ehPLdB4byb #Rheumatology #Autoimmunity #RNL2026 https://t.co/nLEPM3REi4

Adjunctive Prednisolone for Kawasaki Disease An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients. https://t.co/dS1uwufh69 https://t.co/wpxyOYXp8l

Leeds study of 63 pts w/ palindromic rheumatism (PR) progressed to Persistent IA (PIA) @ median 13.4 mos, hands predominating across flares. PIA developed in joints involved in PR flares in 71% of pts. @RA Dx, PR onset pts had signif higher swollen joints(4.1 vs 3.2) https://t.co/g2vjfVjDlK

Gabapentinoid use 2008-2018: worldwide there was an annual incr of +17.2% (from 4.2/d to 18.3/d per 10K pop. Highest gaba use in high income countries, 6X higher than lower income (40/d vs 6.1/d) https://t.co/jXjxNj1Uyz https://t.co/GmQJ3UGGw9